Mental Health Services

(asked on 25th July 2019) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the (a) efficacy and (b) cost of the use of (i) anti-depressant drugs and (ii) mindfulness-based stress reduction therapy and mindfulness cognitive behaviour therapy.


Answered by
Nadine Dorries Portrait
Nadine Dorries
This question was answered on 9th September 2019

The Medicines and Healthcare products Regulatory Agency is responsible for the regulation of medicines used in the United Kingdom, including efficacy. Anti-depressant medicines licensed in the UK have been approved after robust supporting data has been submitted to demonstrate the quality, safety and efficacy of the product for the condition it is intended to treat. For a medicine to be licenced, the benefit to risk balance should be positive.

The National Institute for Health and Care Excellence (NICE) examines evidence of clinical and cost effectiveness when providing guidelines and recommendations of treatment. Presently, mindfulness-based therapy is only recommended for the treatment of depression in adults. NICE pathways bring together everything NICE says on a topic. The pathway for depression, including antidepressant treatment, is available at the following link:

https://pathways.nice.org.uk/pathways/depression

Reticulating Splines